SCHEMBL14073740

SCHEMBL14073740

O=C(Cc1cccs1)Nc1ccc2c(c1)OCC(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NSD2 O96028 1/20 0.56
▸ MEN1 O00255 8/20 0.51
▸ KMT2A Q03164 8/20 0.51
▸ POLB P06746 5/20 0.51
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ RAB9A P51151 6/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ ESR1 P03372 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ NPC1 O15118 5/20 0.49
▸ TP53 P04637 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ BLM P54132 2/20 0.49
▸ HPGD P15428 1/20 0.48
▸ TRPV1 Q8NER1 1/20 0.48
▸ MAPT P10636 1/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14073519 0.91 KMT2A (0.55) NSD2MEN1KMT2APOLBSMN1; SMN2
SCHEMBL14073735 0.82 KMT2A (0.61) NSD2MEN1KMT2APOLBSMN1; SMN2
SCHEMBL14073742 0.81 RAB9A (0.64) NSD2KMT2APOLBSMN1; SMN2RAB9A
SCHEMBL4577333 0.80 ALDH1A1 (0.57) KMT2APOLBSMN1; SMN2RAB9AALDH1A1
SCHEMBL14073688 0.80 PARP1 (0.54) KMT2APOLBALDH1A1TSHRTRPV1
SCHEMBL14073866 0.78 ROCK2 (0.63) —
SCHEMBL14073861 0.76 CYP3A4 (0.48) NSD2KMT2APOLBRAB9AALDH1A1
SCHEMBL14073196 0.76 HPGD (0.64) MEN1KMT2APOLBSMN1; SMN2RAB9A
SCHEMBL14073718 0.76 TRPV1 (0.53) KMT2APOLBALDH1A1TRPV1MAPT
SCHEMBL14073761 0.76 MAPT (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety MMP12, MMP13, MMP25 NSD2 3058/4885MEN1 1893/4885KMT2A 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback